Table 1

Expression microarray studies used in the meta-analysis

Study [Reference]

Platform

Unique Genes Tested

Genes Sig Up

(% of tested)

Genes Sig Down

(% of tested)

Primary tumors

Distant Mets

GEO Accession


1

Bittner Breast [14]

HG U133 Plus 2.0

19079

33

(0.2%)

0

(0%)

327

9

GSE2109

2

Bittner Colon [14]

HG U133 Plus 2.0

19079

656

(3.4%)

3938

(20.6%)

330

43

GSE2109

3

Bittner Lung [14]

HG U133 Plus 2.0

19079

127

(0.6%)

15

(0.1%)

101

8

GSE2109

4

Bittner Ovarian [14]

HG U133 Plus 2.0

19079

494

(2.6%)

131

(0.7%)

166

75

GSE2109

5

Bittner Sarcoma [14]

HG U133 Plus 2.0

19079

4

(0%)

1

(0%)

42

10

GSE2109

6

Garber Lung [16]

Institutional cDNA microarray

10723

9

(0.1%)

57

(0.5%)

61

6

GSE3398

7

Graudens Colon [17]

Institutional cDNA microarray

6242

145

(2.3%)

80

(1.3%)

18

30

GSE3964

8

Haqq Melanoma [18]

Research Genetics cDNA microarray

7344

420

(5.7%)

639

(8.7%)

6

19

N/A

9

Holzbeierlein Prostate [19]

HG U95A-Av2

7820

11

(0.1%)

295

(3.8%)

40

9

N/A

10

Jain Endocrine [20]

HG U95A-Av2

7820

14

(0.2%)

229

(2.9%)

8

17

N/A

11

Lapointe Prostate [22]

Institutional cDNA microarray

10021

1081

(10.8%)

1219

(12.2%)

62

9

GSE3933

12

LaTulippe Prostate [23]

HG U95A-Av2

7820

265

(3.4%)

245

(3.1%)

23

9

N/A

13

Magee Prostate [26]

HG FL

4564

35

(0.8%)

18

(0.4%)

8

3

N/A

14

O'Donnell Oral [30]

HG U133A

12427

1

(0%)

28

(0.2%)

22

5

GSE2280

15

Radvanyi Breast [31]

Custom cDNA microarray

16133

548

(3.3%)

85

(0.5%)

47

7

GSE1477

16

Ramaswamy Multicancer [32]

HG FL, Hu35KsubA

9064

556

(3.4%)

301

(3.3%)

10

4

N/A

17

Segal Sarcoma [34]

HG U95A-Av2

7820

168

(2.1%)

164

(2.1%)

29

4

N/A

18

Vanaja Prostate [38]

HG U133A,

HG U133B

17358

4

(0%)

208

(1.2%)

27

5

N/A


The 18 datasets used in the meta-analysis are described with regard to the platform used in the original experiment, the number of unique genes represented in the platform, the number of genes significantly (sig) dysregulated in metastases compared with primaries with a Q-value < 0.1, the number of samples that are primary tumors or distant metastases (mets), and the Gene Expression Omnibus (GEO) Accession number. HG U133 Plus 2: Affymetrix Human Genome U133 Plus 2.0 Array; HG U95A0Av2: Affymetrix Human Genome U95A-Av2 Array; HG FL: Affymetrix HumanGeneFL Array; HG U133A: Affymetrix Human Genome U133A Array: HG U133B: Affymetrix Human Genome U133B Array; N/A: Not applicable.

Daves et al. BMC Medical Genomics 2011 4:56   doi:10.1186/1755-8794-4-56

Open Data